Investors & Media

Investors & Media

Corporate Profile

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Our lead product candidate, PLN-74809, is an orally available small molecule designed to be a selective inhibitor of αvβ1 and αvβ6, two integrins that play key roles in multiple fibrotic pathways. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). We are currently conducting Phase 2a trials of PLN-74809 for the treatment of IPF and plan to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant’s second clinical stage product candidate, PLN-1474, is designed to be a small molecule selective inhibitor of αvβ1, targeting liver fibrosis associated with nonalcoholic steatohepatitis (NASH) and is partnered with Novartis. PLN-1474 is currently in Phase 1 testing. In addition to our clinical stage programs, we currently have preclinical programs targeting oncology and muscular dystrophies.

Investor Contact:

Christopher Keenan
VP, Investor Relations and Corporate Communications
(650) 481-6770
ir@pliantrx.com

Media Contact:

Cambria Fuqua
Canale Communications
(619) 849-5390
cambria@canalecomm.com

Copyright © 2020 Pliant Therapeutics, Inc. | All Rights Reserved | Terms of Use